International Journal of Applied and Basic Medical Research

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 10  |  Issue : 2  |  Page : 97--101

Effect of Vitamin K epoxide reductase complex 1 polymorphism on warfarin dose requirement among patients in tertiary care hospital


Sahana Hadihalli Veeregowda1, Bhuvana Krishnaswamy1, Sharath Balakrishna2, 3 
1 Department of Pharmacology, Sri Devaraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and Research, Kolar, Karnataka, India
2 Department of Cell Biology and Molecular Genetics, Sri Devaraj Urs Academy of Higher Education and Research, Kolar, Karnataka, India

Correspondence Address:
Bhuvana Krishnaswamy
Department of Pharmacology, Sri Devaraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and Research, Tamaka, Kolar, Karnataka
India

Background: Warfarin, anticoagulant is used for thromboembolic disorders. Inter-individual variation in clinical response to warfarin is due to various factors, including polymorphism of Vitamin K epoxide reductase complex 1 (VKORC1)-1639G>A. The aim of our study was to evaluate the effect of VKORC1 polymorphism on the maintenance dose of warfarin. Materials and Methods: Cross-sectional study conducted by the departments of Pharmacology, Cell Biology and Molecular Genetics on patients attending cardiology clinic, receiving warfarin for at least 2 months. Genomic deoxyribonucleic acid was extracted and genotyping was done by Polymerase Chain Reaction - Restriction Fragment Length Polymorphism. The correlation between VKORC1 gene polymorphism and warfarin maintenance dose was analyzed. Results: A total of 102 patients with a mean age of 47.72 ± 10.31 years, of which 58 (56.86%) were male. The frequency of VKORC1 G>A for GG, GA, and AA genotypes was 74.51%, 19.61%, and 5.88%, respectively. Variant allele AA was less frequent than the wild type. Mean weekly warfarin dose was 23.12 ± 8.08, 22.93 ± 8.21, and 15.6 ± 5.35 mg in patients with GG, GA, and AA genotypes, respectively. Patients with GG genotype required therapeutic dose compared to variant type (P = 0.001). Multiple stepwise regression model showed 26.3% variability in warfarin dose was due to VKORC1 genotype (R = 0.513, R2 = 0.263, adjusted R2 = 0.256, P = 0.0001). Conclusion: VKORC1 polymorphism alone influence 26.3% variability in warfarin dose and AA genotype patients required lower dose.


How to cite this article:
Veeregowda SH, Krishnaswamy B, Balakrishna S,. Effect of Vitamin K epoxide reductase complex 1 polymorphism on warfarin dose requirement among patients in tertiary care hospital.Int J App Basic Med Res 2020;10:97-101


How to cite this URL:
Veeregowda SH, Krishnaswamy B, Balakrishna S,. Effect of Vitamin K epoxide reductase complex 1 polymorphism on warfarin dose requirement among patients in tertiary care hospital. Int J App Basic Med Res [serial online] 2020 [cited 2021 Jan 15 ];10:97-101
Available from: https://www.ijabmr.org/article.asp?issn=2229-516X;year=2020;volume=10;issue=2;spage=97;epage=101;aulast=Veeregowda;type=0